- Personalized medicine can pave the way for the safe use of CB(1) receptor antagonists
[作者:Lazary, J; Juhasz, G; Hunyady, L; Bagdy, G,期刊:Trends in Pharmacological Sciences, 页码:270-280 , 文章类型: Review,,卷期:2011年32-5]
- Antagonists of cannabinoid type-1 (CB(1)) receptors have been explored as therapeutic agents for obesity and addiction. However, use of rimonabant (the first marketed CB, receptor antagonist) has been suspended due to it...
|